Modiblast Pharma

Modiblast Pharma, founded in 2018 and based in Munich, is a preclinical-stage biotech pioneering an in vivo cell reprogramming platform for oncology. The company's core technology, following a 'Trojan horse' motif, seeks to reprogram cancer cells to stimulate innate and adaptive immunity, with the goal of creating a backbone maintenance therapy to extend remission. Currently raising its seed round, Modiblast is progressing its lead candidate, MB101, a fixed-dose combination for AML, toward a first-in-human trial. The long-term vision includes developing a self-administerable, at-home therapy to improve patient quality of life.

Proprietary in vivo cell reprogramming platform designed to convert cancer cells into antigen-presenting cells (APCs) following a 'Trojan horse' motif, triggering a personalized anti-tumor immune response.

Modiblast operates in the highly competitive AML and immuno-oncology space, competing against targeted therapies, antibody-drug conjugates, and ex vivo cell therapies. Its key differentiation is the in vivo, off-the-shelf approach aiming to avoid the complexity and cost of ex vivo cell manufacturing.